TY - JOUR
T1 - Genetic mouse models relevant to schizophrenia
T2 - Taking stock and looking forward
AU - Harrison, Paul J.
AU - Pritchett, David
AU - Stumpenhorst, Katharina
AU - Betts, Jill F.
AU - Nissen, Wiebke
AU - Schweimer, Judith
AU - Lane, Tracy
AU - Burnet, Philip W.J.
AU - Lamsa, Karri P.
AU - Sharp, Trevor
AU - Bannerman, David M.
AU - Tunbridge, Elizabeth M.
N1 - Funding Information:
DP holds the University of Oxford Christopher Welch Scholarship. KS is funded by a studentship from the Wellcome Trust. JB is funded by a studentship from the Medical Research Council (MRC). WN holds a Department of Pharmacology studentship. KPL is a Wellcome Trust Career Development Fellow. DMB is a Wellcome Trust Senior Research Fellow. EMT is a Royal Society University Research Fellow. Our work is also supported by grants from MRC , BBSRC , and the BMA Margaret Temple Fellowship .
PY - 2012/3
Y1 - 2012/3
N2 - Genetic mouse models relevant to schizophrenia complement, and have to a large extent supplanted, pharmacological and lesion-based rat models. The main attraction is that they potentially have greater construct validity; however, they share the fundamental limitations of all animal models of psychiatric disorder, and must also be viewed in the context of the uncertain and complex genetic architecture of psychosis. Some of the key issues, including the choice of gene to target, the manner of its manipulation, gene-gene and gene-environment interactions, and phenotypic characterization, are briefly considered in this commentary, illustrated by the relevant papers reported in this special issue. This article is part of a Special Issue entitled 'Schizophrenia'.
AB - Genetic mouse models relevant to schizophrenia complement, and have to a large extent supplanted, pharmacological and lesion-based rat models. The main attraction is that they potentially have greater construct validity; however, they share the fundamental limitations of all animal models of psychiatric disorder, and must also be viewed in the context of the uncertain and complex genetic architecture of psychosis. Some of the key issues, including the choice of gene to target, the manner of its manipulation, gene-gene and gene-environment interactions, and phenotypic characterization, are briefly considered in this commentary, illustrated by the relevant papers reported in this special issue. This article is part of a Special Issue entitled 'Schizophrenia'.
U2 - 10.1016/j.neuropharm.2011.08.009
DO - 10.1016/j.neuropharm.2011.08.009
M3 - Comment/debate
C2 - 21864547
AN - SCOPUS:84856093355
SN - 0028-3908
VL - 62
SP - 1164
EP - 1167
JO - Neuropharmacology
JF - Neuropharmacology
IS - 3
ER -